What is Obstructive Sleep Apnea?

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Whether you share a bed with someone or sleep alone, here’s your chance to learn what obstructive sleep apnea is, how it occurs, signs and symptoms you should look out for and what you can do to get a better night’s sleep.

The post What is Obstructive Sleep Apnea? appeared first on Medical News Bulletin.

IL-6 inhibitors may protect against diabetic retinopathy

Patients with diabetes who were treated with interleukin-6 inhibitors had significantly lower risk for diabetic retinopathy, potentially pointing to a new treatment pathway, according to data published in Ophthalmology.
“We’ve long understood that diabetic retinopathy is not purely a microvascular disease; it is heavily driven by a secondary arm of chronic inflammation,” Ehsan Rahimy, MD, adjunct clinical associate professor of ophthalmology at Stanford University School of Medicine, told Healio. “IL-6 is a critical regulator in this inflammatory cascade and is known to

20-year-old man with severe upper extremity contracture

We present the case of a 20-year-old man with cerebral palsy-spastic quadriplegia Gross Motor Function Classification System level 5 and right upper extremity Manual Ability Classification System level 5.
Before this surgery, he had been managed nonoperatively with physical and occupational therapy, bracing and botulinum toxin injections. Despite this, he developed severe fixed flexion deformities of the right upper extremity.
He now presents with bilateral lower extremity and right upper extremity contractures that limit his brace tolerance and care. On examination, the patient demonstrated

Imvionix acquires commercial rights to Beovu in US, Canada

Editor’s note: This is a developing story. Please check back soon for updates.
Imvionix has acquired the commercial rights to Beovu in the United States and Canada, according to a press release.
The company acquired Beovu (brolucizumab-dbll) from Novartis. Financial terms of the deal were not announced.
Beovu is an intravitreally injected VEGF inhibitor that is FDA approved for the treatment of wet age-related macular degeneration and diabetic macular edema.
Imvionix, which was founded in 2025, believes its connections in the retina space will expand Beovu’s reach, according to the release.

Exposure to petroleum-based lubricants tied to increased MS risk

Occupational exposure to petroleum-derived lubricants was associated with increased risk for MS, an association that became stronger among smokers and people with genetic susceptibility, according to research published in Neurology.
The potential for petroleum-based lubricants to increase risk for MS had not previously been studied, said Anna Karin Hedström, MD, PhD, a senior research specialist with Karolinska Institutet.
“We thought an association was plausible,” Hedström told Healio. “Smoking and exposure to organic solvents have both been linked to MS, and it is possible that repeated

Q&A: Can combining two diets help prolong life?

ORLANDO — A scientific diet joining two popular patterns could be helpful for longevity, according to a speaker at the American College of Lifestyle Medicine annual meeting.
Valter Longo, PhD, the Edna Jones Professor of Gerontology and a professor of biological science at the University of Southern California Leonard Davis School of Gerontology, offered a presentation on the interconnected issues of diet, longevity and disease.
Healio spoke with Longo, who is also the director of the USC Longevity Institute, to learn more about the two diets he focused on, who benefits the most from them and

Study: Protection from RSV vaccine continues to wane for nursing home residents

WASHINGTON — Vaccination was associated with a “meaningful reduction” in risk for respiratory syncytial virus over three seasons among nursing home residents, but that protection waned over time, researchers reported at IDWeek.
The study assessed Pfizer’s bivalent RSV vaccine, RSVpreF, which was approved in 2023 based on data from a phase 3 trial that evaluated the efficacy and safety of a single dose of the vaccine among adults aged 60 years or older. In the trial, the vaccine demonstrated 66.7% (96.66% CI, 28.8%-85.8%) efficacy against RSV-associated lower respiratory tract illness and 85.7%

IOLs may experience adverse effects in space

One day in the not-so-distant future, someone is going to need cataract surgery in space, J. Morgan Micheletti, MD, FACS, said at the European Society of Cataract and Refractive Surgeons meeting.
To do that, Micheletti said, researchers will to need to figure out how to ship IOLs from Earth to space. That is the focus of his team’s research — understanding how exposure on the exterior of the International Space Station (ISS) affects IOLs.
The easy solution would be to ship lenses in climate-controlled crew cabin storage, but that can be expensive. Instead, Micheletti’s team designed carriers to

CRISPR gene-editing therapy lowers triglycerides in early study

CHICAGO — A gene-editing therapy targeting hepatic ANGPTL3 lowered triglycerides in patients with severe hypertriglyceridemia, according to results of a phase 1b study presented at the American Heart Association Scientific Sessions.
Ashish Sarraju, MD, cardiologist in the section of preventive cardiology in the Tomsich Family Department of Cardiovascular Medicine of The Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, presented the results of the study of 10 patients (median age, 56.5 years; 60% men; median triglycerides, 1,067.7 mg/dL) who received

Physiology-guided care may be best in multivessel CAD

One-third of lesions with severe stenosis were deemed functionally nonsignificant based on a physiology-guided percutaneous coronary intervention approach in patients with multivessel coronary artery disease, a speaker reported.
Evaluating stenosis severity based on angiography may not be adequate to identify potentially flow-limiting stenosis in patients with multivessel CAD, according to a substudy of the AIR-STEMI trial presented at TCT 2026.
The AIR-STEMI trial compared functional coronary angiography-guided vs. conventional angiography-guided complete revascularization in patients with